294 related articles for article (PubMed ID: 30704223)
1. [Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia].
Han X; Bai BB; Wang CJ; Zhao S; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):17-23. PubMed ID: 30704223
[No Abstract] [Full Text] [Related]
2. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Pemmaraju N; Gerds AT; Yu J; Parasuraman S; Shah A; Xi A; Kumar S; Scherber RM; Verstovsek S
Leuk Res; 2022 Apr; 115():106809. PubMed ID: 35220060
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.
Krečak I; Holik H; Martina MP; Zekanović I; Coha B; Gverić-Krečak V
Int J Hematol; 2020 Sep; 112(3):377-384. PubMed ID: 32514928
[TBL] [Abstract][Full Text] [Related]
5. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
6. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
Pósfai É; Marton I; Borbényi Z; Nemes A
Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
8. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
10. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
11. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
[TBL] [Abstract][Full Text] [Related]
12. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
Chou YS; Gau JP; Yu YB; Pai JT; Hsiao LT; Liu JH; Hong YC; Liu CY; Yang CF; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
14. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
15. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
16. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
18. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
19. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
Pearson TC
Semin Oncol; 2002 Jun; 29(3 Suppl 10):16-21. PubMed ID: 12096353
[TBL] [Abstract][Full Text] [Related]
20. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
